Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment

Clin Infect Dis. 2003 Feb 1;36(3):e47-9. doi: 10.1086/345746. Epub 2003 Jan 16.

Abstract

Treatment with the chimeric anti-CD20 monoclonal antibody rituximab induces rapid and long-lasting depletion of circulating B cells. We report the occurrence of enteroviral meningoencephalitis following rituximab therapy in 1 child with immune thrombocytopenia and in 1 adult patient with relapsed B cell lymphoma.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20 / immunology*
  • Antineoplastic Agents / adverse effects*
  • Child
  • Humans
  • Meningoencephalitis / chemically induced*
  • Middle Aged
  • Rituximab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20
  • Antineoplastic Agents
  • Rituximab